Proactiveinvestors Australia Pharmaxis Ltd https://www.proactiveinvestors.com.au Proactiveinvestors Australia Pharmaxis Ltd RSS feed en Wed, 08 Jul 2020 15:29:56 +1000 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) Pharmaxis Ltd expects review of Bronchitol NDA to be completed by mid-2020 https://www.proactiveinvestors.com.au/companies/news/918961/pharmaxis-ltd-expects-review-of-bronchitol-nda-to-be-completed-by-mid-2020-918961.html Wed, 06 May 2020 10:01:00 +1000 https://www.proactiveinvestors.com.au/companies/news/918961/pharmaxis-ltd-expects-review-of-bronchitol-nda-to-be-completed-by-mid-2020-918961.html Pharmaxis US licensee Chiesi files resubmission for Bronchitol with FDA, sets clock ticking for potential launch and US$10 million cash milestone https://www.proactiveinvestors.com.au/companies/news/918801/pharmaxis-us-licensee-chiesi-files-resubmission-for-bronchitol-with-fda-sets-clock-ticking-for-potential-launch-and-us10-million-cash-milestone-918801.html Tue, 05 May 2020 05:16:00 +1000 https://www.proactiveinvestors.com.au/companies/news/918801/pharmaxis-us-licensee-chiesi-files-resubmission-for-bronchitol-with-fda-sets-clock-ticking-for-potential-launch-and-us10-million-cash-milestone-918801.html Pharmaxis strengthens board through appointment of Dr Neil Graham https://www.proactiveinvestors.com.au/companies/news/918686/pharmaxis-strengthens-board-through-appointment-of-dr-neil-graham-918686.html Mon, 04 May 2020 02:37:00 +1000 https://www.proactiveinvestors.com.au/companies/news/918686/pharmaxis-strengthens-board-through-appointment-of-dr-neil-graham-918686.html Pharmaxis eyes partner funding for LOXL2 inhibitor program; CEO to present at virtual health conference https://www.proactiveinvestors.com.au/companies/news/918461/pharmaxis-eyes-partner-funding-for-loxl2-inhibitor-program-ceo-to-present-at-virtual-health-conference-918461.html Thu, 30 Apr 2020 06:28:00 +1000 https://www.proactiveinvestors.com.au/companies/news/918461/pharmaxis-eyes-partner-funding-for-loxl2-inhibitor-program-ceo-to-present-at-virtual-health-conference-918461.html Pharmaxis to progress myelofibrosis drug to Phase II following positive results https://www.proactiveinvestors.com.au/companies/news/918279/pharmaxis-to-progress-myelofibrosis-drug-to-phase-ii-following-positive-results-918279.html Tue, 28 Apr 2020 08:57:00 +1000 https://www.proactiveinvestors.com.au/companies/news/918279/pharmaxis-to-progress-myelofibrosis-drug-to-phase-ii-following-positive-results-918279.html Pharmaxis cancer drug ready to start myelofibrosis phase 2 studies this year https://www.proactiveinvestors.com.au/companies/news/918224/pharmaxis-cancer-drug-ready-to-start-myelofibrosis-phase-2-studies-this-year-918224.html Tue, 28 Apr 2020 01:09:00 +1000 https://www.proactiveinvestors.com.au/companies/news/918224/pharmaxis-cancer-drug-ready-to-start-myelofibrosis-phase-2-studies-this-year-918224.html Pharmaxis advancing anti fibrotic compounds towards phase 2 clinical trials; Bronchitol sales rise with FDA decision expected mid-year https://www.proactiveinvestors.com.au/companies/news/911928/pharmaxis-advancing-anti-fibrotic-compounds-towards-phase-2-clinical-trials-bronchitol-sales-rise-with-fda-decision-expected-mid-year-911928.html Fri, 31 Jan 2020 04:14:00 +1100 https://www.proactiveinvestors.com.au/companies/news/911928/pharmaxis-advancing-anti-fibrotic-compounds-towards-phase-2-clinical-trials-bronchitol-sales-rise-with-fda-decision-expected-mid-year-911928.html Pharmaxis resourced to complete partnering and clinical development milestones https://www.proactiveinvestors.com.au/companies/news/909412/pharmaxis-resourced-to-complete-partnering-and-clinical-development-milestones-909412.html Wed, 18 Dec 2019 01:36:00 +1100 https://www.proactiveinvestors.com.au/companies/news/909412/pharmaxis-resourced-to-complete-partnering-and-clinical-development-milestones-909412.html Pharmaxis anti-fibrotic pipeline review highlights drug with strong pre-clinical data for bone marrow cancer myelofibrosis https://www.proactiveinvestors.com.au/companies/news/905891/pharmaxis-anti-fibrotic-pipeline-review-highlights-drug-with-strong-pre-clinical-data-for-bone-marrow-cancer-myelofibrosis-905891.html Wed, 30 Oct 2019 05:01:00 +1100 https://www.proactiveinvestors.com.au/companies/news/905891/pharmaxis-anti-fibrotic-pipeline-review-highlights-drug-with-strong-pre-clinical-data-for-bone-marrow-cancer-myelofibrosis-905891.html Pharmaxis licensee receives US FDA guidance on Bronchitol approval steps https://www.proactiveinvestors.com.au/companies/news/905691/pharmaxis-licensee-receives-us-fda-guidance-on-bronchitol-approval-steps-905691.html Mon, 28 Oct 2019 03:29:00 +1100 https://www.proactiveinvestors.com.au/companies/news/905691/pharmaxis-licensee-receives-us-fda-guidance-on-bronchitol-approval-steps-905691.html Pharmaxis begins dosing patients in phase Ib study https://www.proactiveinvestors.com.au/companies/news/905503/pharmaxis-begins-dosing-patients-in-phase-ib-study-905503.html Thu, 24 Oct 2019 04:36:00 +1100 https://www.proactiveinvestors.com.au/companies/news/905503/pharmaxis-begins-dosing-patients-in-phase-ib-study-905503.html Pharmaxis cash funds for development of new drugs boosted by $6.2 million R&D tax incentive https://www.proactiveinvestors.com.au/companies/news/904998/pharmaxis-cash-funds-for-development-of-new-drugs-boosted-by-62-million-rd-tax-incentive-904998.html Thu, 17 Oct 2019 01:24:00 +1100 https://www.proactiveinvestors.com.au/companies/news/904998/pharmaxis-cash-funds-for-development-of-new-drugs-boosted-by-62-million-rd-tax-incentive-904998.html Pharmaxis features in APAC’s top 100 most innovative pharma companies report https://www.proactiveinvestors.com.au/companies/news/902531/pharmaxis-features-in-apacs-top-100-most-innovative-pharma-companies-report-902531.html Thu, 12 Sep 2019 00:17:00 +1000 https://www.proactiveinvestors.com.au/companies/news/902531/pharmaxis-features-in-apacs-top-100-most-innovative-pharma-companies-report-902531.html Pharmaxis hopeful of FDA approval for cystic fibrosis inhalation medicine Bronchitol by Q1 2020 https://www.proactiveinvestors.com.au/companies/news/900583/pharmaxis-hopeful-of-fda-approval-for-cystic-fibrosis-inhalation-medicine-bronchitol-by-q1-2020-900583.html Tue, 13 Aug 2019 02:19:00 +1000 https://www.proactiveinvestors.com.au/companies/news/900583/pharmaxis-hopeful-of-fda-approval-for-cystic-fibrosis-inhalation-medicine-bronchitol-by-q1-2020-900583.html Pharmaxis continues to add value to portfolio assets; Bronchitol reaches pivotal stage https://www.proactiveinvestors.com.au/companies/news/224464/pharmaxis-continues-to-add-value-to-portfolio-assets-bronchitol-reaches-pivotal-stage-224464.html Thu, 25 Jul 2019 03:52:00 +1000 https://www.proactiveinvestors.com.au/companies/news/224464/pharmaxis-continues-to-add-value-to-portfolio-assets-bronchitol-reaches-pivotal-stage-224464.html Pharmaxis on track to complete FDA approval process for Bronchitol in Q1 2020 https://www.proactiveinvestors.com.au/companies/news/222458/pharmaxis-on-track-to-complete-fda-approval-process-for-bronchitol-in-q1-2020-222458.html Thu, 20 Jun 2019 02:31:00 +1000 https://www.proactiveinvestors.com.au/companies/news/222458/pharmaxis-on-track-to-complete-fda-approval-process-for-bronchitol-in-q1-2020-222458.html Pharmaxis expects an FDA decision on Bronchitol mid-year after positive committee recommendation https://www.proactiveinvestors.com.au/companies/news/313328/pharmaxis-expects-an-fda-decision-on-bronchitol-mid-year-after-positive-committee-recommendation-13328.html Tue, 14 May 2019 00:23:00 +1000 https://www.proactiveinvestors.com.au/companies/news/313328/pharmaxis-expects-an-fda-decision-on-bronchitol-mid-year-after-positive-committee-recommendation-13328.html Pharmaxis welcomes US FDA committee’s recommendation on use of Bronchitol in CF https://www.proactiveinvestors.com.au/companies/news/219929/pharmaxis-welcomes-us-fda-committees-recommendation-on-use-of-bronchitol-in-cf-219929.html Thu, 09 May 2019 02:55:00 +1000 https://www.proactiveinvestors.com.au/companies/news/219929/pharmaxis-welcomes-us-fda-committees-recommendation-on-use-of-bronchitol-in-cf-219929.html Pharmaxis prepares for advisory committee meeting on use of Bronchitol in the US https://www.proactiveinvestors.com.au/companies/news/217177/pharmaxis-prepares-for-advisory-committee-meeting-on-use-of-bronchitol-in-the-us-217177.html Tue, 26 Mar 2019 02:12:00 +1100 https://www.proactiveinvestors.com.au/companies/news/217177/pharmaxis-prepares-for-advisory-committee-meeting-on-use-of-bronchitol-in-the-us-217177.html Pharmaxis gains new substantial holder with 6.89% interest https://www.proactiveinvestors.com.au/companies/news/215758/pharmaxis-gains-new-substantial-holder-with-689-interest-215758.html Tue, 05 Mar 2019 00:57:00 +1100 https://www.proactiveinvestors.com.au/companies/news/215758/pharmaxis-gains-new-substantial-holder-with-689-interest-215758.html Pharmaxis sees progress in Boehringer Ingelheim’s clinical trial in patients with NASH https://www.proactiveinvestors.com.au/companies/news/215174/pharmaxis-sees-progress-in-boehringer-ingelheims-clinical-trial-in-patients-with-nash-215174.html Mon, 25 Feb 2019 03:37:00 +1100 https://www.proactiveinvestors.com.au/companies/news/215174/pharmaxis-sees-progress-in-boehringer-ingelheims-clinical-trial-in-patients-with-nash-215174.html Pharmaxis begins phase one clinical trial of compound targeting pancreatic cancer https://www.proactiveinvestors.com.au/companies/news/215089/pharmaxis-begins-phase-one-clinical-trial-of-compound-targeting-pancreatic-cancer-215089.html Fri, 22 Feb 2019 03:57:00 +1100 https://www.proactiveinvestors.com.au/companies/news/215089/pharmaxis-begins-phase-one-clinical-trial-of-compound-targeting-pancreatic-cancer-215089.html Pharmaxis well funded as potential partners assess its anti‐fibrotic mechanisms https://www.proactiveinvestors.com.au/companies/news/213663/pharmaxis-well-funded-as-potential-partners-assess-its-antifibrotic-mechanisms-213663.html Thu, 31 Jan 2019 03:15:00 +1100 https://www.proactiveinvestors.com.au/companies/news/213663/pharmaxis-well-funded-as-potential-partners-assess-its-antifibrotic-mechanisms-213663.html Pharmaxis LOXL2 program phase 2 ready after completion of 13-week toxicity studies https://www.proactiveinvestors.com.au/companies/news/212738/pharmaxis-loxl2-program-phase-2-ready-after-completion-of-13-week-toxicity-studies-212738.html Thu, 17 Jan 2019 02:21:00 +1100 https://www.proactiveinvestors.com.au/companies/news/212738/pharmaxis-loxl2-program-phase-2-ready-after-completion-of-13-week-toxicity-studies-212738.html Pharmaxis resubmits new drug application for Bronchitol in the US https://www.proactiveinvestors.com.au/companies/news/211533/pharmaxis-resubmits-new-drug-application-for-bronchitol-in-the-us-211533.html Thu, 20 Dec 2018 02:47:00 +1100 https://www.proactiveinvestors.com.au/companies/news/211533/pharmaxis-resubmits-new-drug-application-for-bronchitol-in-the-us-211533.html Pharmaxis reveals first sales of Aridol® in US following successful relaunch https://www.proactiveinvestors.com.au/companies/news/211098/pharmaxis-reveals-first-sales-of-aridol-in-us-following-successful-relaunch-211098.html Thu, 13 Dec 2018 00:53:00 +1100 https://www.proactiveinvestors.com.au/companies/news/211098/pharmaxis-reveals-first-sales-of-aridol-in-us-following-successful-relaunch-211098.html Pharmaxis advancing partnership talks for LOXL2, starting pancreatic cancer program https://www.proactiveinvestors.com.au/companies/news/311300/pharmaxis-advancing-partnership-talks-for-loxl2-starting-pancreatic-cancer-program-11300.html Fri, 23 Nov 2018 03:03:00 +1100 https://www.proactiveinvestors.com.au/companies/news/311300/pharmaxis-advancing-partnership-talks-for-loxl2-starting-pancreatic-cancer-program-11300.html Pharmaxis moving into phase I clinical trial of its small molecule LOX inhibitor https://www.proactiveinvestors.com.au/companies/news/209514/pharmaxis-moving-into-phase-i-clinical-trial-of-its-small-molecule-lox-inhibitor-209514.html Tue, 20 Nov 2018 02:11:00 +1100 https://www.proactiveinvestors.com.au/companies/news/209514/pharmaxis-moving-into-phase-i-clinical-trial-of-its-small-molecule-lox-inhibitor-209514.html Pharmaxis receives positive results from clinical trial of treatment for fibrotic diseases https://www.proactiveinvestors.com.au/companies/news/209233/pharmaxis-receives-positive-results-from-clinical-trial-of-treatment-for-fibrotic-diseases-209233.html Wed, 14 Nov 2018 23:30:00 +1100 https://www.proactiveinvestors.com.au/companies/news/209233/pharmaxis-receives-positive-results-from-clinical-trial-of-treatment-for-fibrotic-diseases-209233.html Pharmaxis receives positive results from LOXL2 clinical trial https://www.proactiveinvestors.com.au/companies/news/206839/pharmaxis-receives-positive-results-from-loxl2-clinical-trial-206839.html Thu, 11 Oct 2018 01:20:00 +1100 https://www.proactiveinvestors.com.au/companies/news/206839/pharmaxis-receives-positive-results-from-loxl2-clinical-trial-206839.html Pharmaxis adds valuable experience with Ed Rayner appointment https://www.proactiveinvestors.com.au/companies/news/205073/pharmaxis-adds-valuable-experience-with-ed-rayner-appointment-205073.html Tue, 18 Sep 2018 02:32:00 +1000 https://www.proactiveinvestors.com.au/companies/news/205073/pharmaxis-adds-valuable-experience-with-ed-rayner-appointment-205073.html Pharmaxis gains Arix Bioscience Plc as a new substantial shareholder https://www.proactiveinvestors.com.au/companies/news/203235/pharmaxis-gains-arix-bioscience-plc-as-a-new-substantial-shareholder-203235.html Mon, 20 Aug 2018 22:05:00 +1000 https://www.proactiveinvestors.com.au/companies/news/203235/pharmaxis-gains-arix-bioscience-plc-as-a-new-substantial-shareholder-203235.html Pharmaxis receives FDA approval to produce Aridol for US market https://www.proactiveinvestors.com.au/companies/news/202908/pharmaxis-receives-fda-approval-to-produce-aridol-for-us-market-202908.html Wed, 15 Aug 2018 02:20:00 +1000 https://www.proactiveinvestors.com.au/companies/news/202908/pharmaxis-receives-fda-approval-to-produce-aridol-for-us-market-202908.html Pharmaxis secures $24 million at premium to support partnering negotiations https://www.proactiveinvestors.com.au/companies/news/202252/pharmaxis-secures-24-million-at-premium-to-support-partnering-negotiations-202252.html Mon, 06 Aug 2018 03:24:00 +1000 https://www.proactiveinvestors.com.au/companies/news/202252/pharmaxis-secures-24-million-at-premium-to-support-partnering-negotiations-202252.html Pharmaxis enters trading halt ahead of share placement https://www.proactiveinvestors.com.au/companies/news/202159/pharmaxis-enters-trading-halt-ahead-of-share-placement-202159.html Fri, 03 Aug 2018 01:41:00 +1000 https://www.proactiveinvestors.com.au/companies/news/202159/pharmaxis-enters-trading-halt-ahead-of-share-placement-202159.html Pharmaxis powering ahead with phase I LOXL2 studies https://www.proactiveinvestors.com.au/companies/news/201702/pharmaxis-powering-ahead-with-phase-i-loxl2-studies-201702.html Fri, 27 Jul 2018 04:39:00 +1000 https://www.proactiveinvestors.com.au/companies/news/201702/pharmaxis-powering-ahead-with-phase-i-loxl2-studies-201702.html Pharmaxis phase I trial attracts interest from multiple pharmaceutical companies https://www.proactiveinvestors.com.au/companies/news/198827/pharmaxis-phase-i-trial-attracts-interest-from-multiple-pharmaceutical-companies-198827.html Thu, 14 Jun 2018 01:58:00 +1000 https://www.proactiveinvestors.com.au/companies/news/198827/pharmaxis-phase-i-trial-attracts-interest-from-multiple-pharmaceutical-companies-198827.html Pharmaxis has the "secret sauce" for developing drugs through to commercialisation https://www.proactiveinvestors.com.au/companies/news/309343/pharmaxis-has-the-secret-sauce-for-developing-drugs-through-to-commercialisation-9343.html Mon, 21 May 2018 23:45:00 +1000 https://www.proactiveinvestors.com.au/companies/news/309343/pharmaxis-has-the-secret-sauce-for-developing-drugs-through-to-commercialisation-9343.html Pharmaxis has key drivers in place for short and long term value creation https://www.proactiveinvestors.com.au/companies/news/309289/pharmaxis-has-key-drivers-in-place-for-short-and-long-term-value-creation-9289.html Tue, 15 May 2018 00:28:00 +1000 https://www.proactiveinvestors.com.au/companies/news/309289/pharmaxis-has-key-drivers-in-place-for-short-and-long-term-value-creation-9289.html Pharmaxis boosts cash position securing sustainable future https://www.proactiveinvestors.com.au/companies/news/196009/pharmaxis-boosts-cash-position-securing-sustainable-future-196009.html Mon, 30 Apr 2018 04:07:00 +1000 https://www.proactiveinvestors.com.au/companies/news/196009/pharmaxis-boosts-cash-position-securing-sustainable-future-196009.html Pharmaxis reveals a quarterly shareholder update full of highlights https://www.proactiveinvestors.com.au/companies/news/309162/pharmaxis-reveals-a-quarterly-shareholder-update-full-of-highlights-9162.html Mon, 30 Apr 2018 00:01:00 +1000 https://www.proactiveinvestors.com.au/companies/news/309162/pharmaxis-reveals-a-quarterly-shareholder-update-full-of-highlights-9162.html Pharmaxis seeing a great deal of interest from potential LOXL2 program partners https://www.proactiveinvestors.com.au/companies/news/308729/pharmaxis-seeing-a-great-deal-of-interest-from-potential-loxl2-program-partners-8729.html Sun, 11 Feb 2018 20:10:00 +1100 https://www.proactiveinvestors.com.au/companies/news/308729/pharmaxis-seeing-a-great-deal-of-interest-from-potential-loxl2-program-partners-8729.html Pharmaxis making strong progress with significant value inflection points ahead https://www.proactiveinvestors.com.au/companies/news/308711/pharmaxis-making-strong-progress-with-significant-value-inflection-points-ahead-8711.html Wed, 07 Feb 2018 04:09:00 +1100 https://www.proactiveinvestors.com.au/companies/news/308711/pharmaxis-making-strong-progress-with-significant-value-inflection-points-ahead-8711.html Pharmaxis outlines share price catalysts for 2018 https://www.proactiveinvestors.com.au/companies/news/190782/pharmaxis-outlines-share-price-catalysts-for-2018-190782.html Mon, 29 Jan 2018 21:33:00 +1100 https://www.proactiveinvestors.com.au/companies/news/190782/pharmaxis-outlines-share-price-catalysts-for-2018-190782.html Pharmaxis strengthens balance sheet with $15 million milestone payment https://www.proactiveinvestors.com.au/companies/news/189839/pharmaxis-strengthens-balance-sheet-with-15-million-milestone-payment-189839.html Thu, 11 Jan 2018 00:55:00 +1100 https://www.proactiveinvestors.com.au/companies/news/189839/pharmaxis-strengthens-balance-sheet-with-15-million-milestone-payment-189839.html Pharmaxis secures further Australian government reimbursement for Bronchitol https://www.proactiveinvestors.com.au/companies/news/189417/pharmaxis-secures-further-australian-government-reimbursement-for-bronchitol-189417.html Tue, 02 Jan 2018 22:07:00 +1100 https://www.proactiveinvestors.com.au/companies/news/189417/pharmaxis-secures-further-australian-government-reimbursement-for-bronchitol-189417.html Pharmaxis takes full control of collaboration on LOXL2 inhibitors and expands scientific program https://www.proactiveinvestors.com.au/companies/news/188760/pharmaxis-takes-full-control-of-collaboration-on-loxl2-inhibitors-and-expands-scientific-program-188760.html Thu, 14 Dec 2017 00:03:00 +1100 https://www.proactiveinvestors.com.au/companies/news/188760/pharmaxis-takes-full-control-of-collaboration-on-loxl2-inhibitors-and-expands-scientific-program-188760.html Pharmaxis boosts its drug discovery ranks https://www.proactiveinvestors.com.au/companies/news/185843/pharmaxis-boosts-its-drug-discovery-ranks-185843.html Thu, 19 Oct 2017 05:35:00 +1100 https://www.proactiveinvestors.com.au/companies/news/185843/pharmaxis-boosts-its-drug-discovery-ranks-185843.html Pharmaxis' CEO Gary Phillips updates on partnership with Boehringer Ingelheim https://www.proactiveinvestors.com.au/companies/news/308045/pharmaxis-ceo-gary-phillips-updates-on-partnership-with-boehringer-ingelheim-8045.html Thu, 07 Sep 2017 22:25:00 +1000 https://www.proactiveinvestors.com.au/companies/news/308045/pharmaxis-ceo-gary-phillips-updates-on-partnership-with-boehringer-ingelheim-8045.html Pharmaxis is set to commence phase 1 trials https://www.proactiveinvestors.com.au/companies/news/308042/pharmaxis-is-set-to-commence-phase-1-trials-8042.html Thu, 07 Sep 2017 06:55:00 +1000 https://www.proactiveinvestors.com.au/companies/news/308042/pharmaxis-is-set-to-commence-phase-1-trials-8042.html Pharmaxis and collaborator Synairgen advance towards human clinical studies https://www.proactiveinvestors.com.au/companies/news/183502/pharmaxis-and-collaborator-synairgen-advance-towards-human-clinical-studies-183502.html Wed, 06 Sep 2017 01:47:00 +1000 https://www.proactiveinvestors.com.au/companies/news/183502/pharmaxis-and-collaborator-synairgen-advance-towards-human-clinical-studies-183502.html Pharmaxis' largest shareholder BVF Partners LP lifts stake https://www.proactiveinvestors.com.au/companies/news/183128/pharmaxis-largest-shareholder-bvf-partners-lp-lifts-stake-183128.html Wed, 30 Aug 2017 01:12:00 +1000 https://www.proactiveinvestors.com.au/companies/news/183128/pharmaxis-largest-shareholder-bvf-partners-lp-lifts-stake-183128.html Pharmaxis gets A$27M injection from Boehringer Ingelheim https://www.proactiveinvestors.com.au/companies/news/307997/pharmaxis-gets-a27m-injection-from-boehringer-ingelheim-7997.html Sun, 27 Aug 2017 22:19:00 +1000 https://www.proactiveinvestors.com.au/companies/news/307997/pharmaxis-gets-a27m-injection-from-boehringer-ingelheim-7997.html Pharmaxis to receive cash injection as Boehringer Ingelheim initiates new trials https://www.proactiveinvestors.com.au/companies/news/182963/pharmaxis-to-receive-cash-injection-as-boehringer-ingelheim-initiates-new-trials-182963.html Fri, 25 Aug 2017 02:22:00 +1000 https://www.proactiveinvestors.com.au/companies/news/182963/pharmaxis-to-receive-cash-injection-as-boehringer-ingelheim-initiates-new-trials-182963.html Pharmaxis receives support for expanded reimbursement of its drug Bronchitol® https://www.proactiveinvestors.com.au/companies/news/182706/pharmaxis-receives-support-for-expanded-reimbursement-of-its-drug-bronchitol-182706.html Mon, 21 Aug 2017 03:36:00 +1000 https://www.proactiveinvestors.com.au/companies/news/182706/pharmaxis-receives-support-for-expanded-reimbursement-of-its-drug-bronchitol-182706.html Pharmaxis enters new quarter positioned for growth https://www.proactiveinvestors.com.au/companies/news/181609/pharmaxis-enters-new-quarter-positioned-for-growth-181609.html Fri, 28 Jul 2017 02:23:00 +1000 https://www.proactiveinvestors.com.au/companies/news/181609/pharmaxis-enters-new-quarter-positioned-for-growth-181609.html Pharmaxis meets primary endpoint of Phase 3 trial of Bronchitol® https://www.proactiveinvestors.com.au/companies/news/179109/pharmaxis-meets-primary-endpoint-of-phase-3-trial-of-bronchitol-179109.html Tue, 13 Jun 2017 00:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/179109/pharmaxis-meets-primary-endpoint-of-phase-3-trial-of-bronchitol-179109.html Pharmaxis Ltd's Gary Phillips reveals completed Phase 3 clinical trial of Bronchitol https://www.proactiveinvestors.com.au/companies/news/307624/pharmaxis-ltd-s-gary-phillips-reveals-completed-phase-3-clinical-trial-of-bronchitol-7624.html Tue, 13 Jun 2017 00:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/307624/pharmaxis-ltd-s-gary-phillips-reveals-completed-phase-3-clinical-trial-of-bronchitol-7624.html Pharmaxis appoints highly-experienced Dr Kathleen Metters to the board https://www.proactiveinvestors.com.au/companies/news/178932/pharmaxis-appoints-highly-experienced-dr-kathleen-metters-to-the-board-178932.html Wed, 07 Jun 2017 23:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/178932/pharmaxis-appoints-highly-experienced-dr-kathleen-metters-to-the-board-178932.html Pharmaxis shares close higher on new cash payment https://www.proactiveinvestors.com.au/companies/news/177821/pharmaxis-shares-close-higher-on-new-cash-payment-177821.html Mon, 15 May 2017 23:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/177821/pharmaxis-shares-close-higher-on-new-cash-payment-177821.html Pharmaxis is now expecting a further cash injection https://www.proactiveinvestors.com.au/companies/news/177765/pharmaxis-is-now-expecting-a-further-cash-injection-177765.html Mon, 15 May 2017 02:30:00 +1000 https://www.proactiveinvestors.com.au/companies/news/177765/pharmaxis-is-now-expecting-a-further-cash-injection-177765.html Pharmaxis 'extremely pleased' following supply agreement with Chiesi Farmaceutici SpA https://www.proactiveinvestors.com.au/companies/news/177467/pharmaxis-extremely-pleased-following-supply-agreement-with-chiesi-farmaceutici-spa-177467.html Mon, 08 May 2017 23:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/177467/pharmaxis-extremely-pleased-following-supply-agreement-with-chiesi-farmaceutici-spa-177467.html Pharmaxis approaching three key potential share price drivers https://www.proactiveinvestors.com.au/companies/news/176557/pharmaxis-approaching-three-key-potential-share-price-drivers-176557.html Wed, 19 Apr 2017 01:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/176557/pharmaxis-approaching-three-key-potential-share-price-drivers-176557.html Pharmaxis’ substantial shareholders increase stakes https://www.proactiveinvestors.com.au/companies/news/175892/pharmaxis-substantial-shareholders-increase-stakes-175892.html Tue, 04 Apr 2017 22:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/175892/pharmaxis-substantial-shareholders-increase-stakes-175892.html Pharmaxis completes treatment phase in clinical trial for U.S. market https://www.proactiveinvestors.com.au/companies/news/173578/pharmaxis-completes-treatment-phase-in-clinical-trial-for-us-market-173578.html Wed, 22 Feb 2017 23:00:00 +1100 https://www.proactiveinvestors.com.au/companies/news/173578/pharmaxis-completes-treatment-phase-in-clinical-trial-for-us-market-173578.html Pharmaxis enters 2017 cashed up as shares strengthen https://www.proactiveinvestors.com.au/companies/news/173287/pharmaxis-enters-2017-cashed-up-as-shares-strengthen-173287.html Thu, 16 Feb 2017 21:00:00 +1100 https://www.proactiveinvestors.com.au/companies/news/173287/pharmaxis-enters-2017-cashed-up-as-shares-strengthen-173287.html Pharmaxis on track for multi-million euro milestone payment https://www.proactiveinvestors.com.au/companies/news/172455/pharmaxis-on-track-for-multi-million-euro-milestone-payment-172455.html Tue, 31 Jan 2017 21:30:00 +1100 https://www.proactiveinvestors.com.au/companies/news/172455/pharmaxis-on-track-for-multi-million-euro-milestone-payment-172455.html Pharmaxis chairman buys shares on market https://www.proactiveinvestors.com.au/companies/news/170142/pharmaxis-chairman-buys-shares-on-market-170142.html Wed, 07 Dec 2016 22:30:00 +1100 https://www.proactiveinvestors.com.au/companies/news/170142/pharmaxis-chairman-buys-shares-on-market-170142.html Pharmaxis Ltd looking like an enticing target for big pharma https://www.proactiveinvestors.com.au/companies/news/169435/pharmaxis-ltd-looking-like-an-enticing-target-for-big-pharma-169435.html Wed, 23 Nov 2016 23:20:00 +1100 https://www.proactiveinvestors.com.au/companies/news/169435/pharmaxis-ltd-looking-like-an-enticing-target-for-big-pharma-169435.html Pharmaxis Ltd gets approval to sell Bronchitol® in largest market yet, Russia https://www.proactiveinvestors.com.au/companies/news/166487/pharmaxis-ltd-gets-approval-to-sell-bronchitol-in-largest-market-yet-russia-71226.html Tue, 27 Sep 2016 00:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/166487/pharmaxis-ltd-gets-approval-to-sell-bronchitol-in-largest-market-yet-russia-71226.html Pharmaxis Ltd stands to gain as NASH biotech acquired for US$1.7B https://www.proactiveinvestors.com.au/companies/news/166413/pharmaxis-ltd-stands-to-gain-as-nash-biotech-acquired-for-us17b-71207.html Mon, 26 Sep 2016 01:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/166413/pharmaxis-ltd-stands-to-gain-as-nash-biotech-acquired-for-us17b-71207.html Pharmaxis Ltd completes first year of new business plan https://www.proactiveinvestors.com.au/companies/news/156140/pharmaxis-ltd-completes-first-year-of-new-business-plan-70111.html Thu, 28 Jul 2016 23:20:00 +1000 https://www.proactiveinvestors.com.au/companies/news/156140/pharmaxis-ltd-completes-first-year-of-new-business-plan-70111.html Pharmaxis Ltd achieves milestone as it targets the U.S. market https://www.proactiveinvestors.com.au/companies/news/156139/pharmaxis-ltd-achieves-milestone-as-it-targets-the-us-market-69844.html Fri, 15 Jul 2016 02:10:00 +1000 https://www.proactiveinvestors.com.au/companies/news/156139/pharmaxis-ltd-achieves-milestone-as-it-targets-the-us-market-69844.html Pharmaxis Ltd targets big pharma at world's largest biotech conference https://www.proactiveinvestors.com.au/companies/news/156138/pharmaxis-ltd-targets-big-pharma-at-worlds-largest-biotech-conference-69418.html Thu, 23 Jun 2016 21:50:00 +1000 https://www.proactiveinvestors.com.au/companies/news/156138/pharmaxis-ltd-targets-big-pharma-at-worlds-largest-biotech-conference-69418.html Pharmaxis cashed up for pathway to drug development https://www.proactiveinvestors.com.au/companies/news/156137/pharmaxis-cashed-up-for-pathway-to-drug-development-68122.html Sun, 17 Apr 2016 23:30:00 +1000 https://www.proactiveinvestors.com.au/companies/news/156137/pharmaxis-cashed-up-for-pathway-to-drug-development-68122.html Pharmaxis Ltd's partner Synairgen plc progresses development of selective inhibitor https://www.proactiveinvestors.com.au/companies/news/156136/pharmaxis-ltds-partner-synairgen-plc-progresses-development-of-selective-inhibitor-67715.html Thu, 24 Mar 2016 05:30:00 +1100 https://www.proactiveinvestors.com.au/companies/news/156136/pharmaxis-ltds-partner-synairgen-plc-progresses-development-of-selective-inhibitor-67715.html Pharmaxis portfolio fires on all pistons as U.S. relations warm up https://www.proactiveinvestors.com.au/companies/news/156135/pharmaxis-portfolio-fires-on-all-pistons-as-us-relations-warm-up-66865.html Thu, 04 Feb 2016 23:30:00 +1100 https://www.proactiveinvestors.com.au/companies/news/156135/pharmaxis-portfolio-fires-on-all-pistons-as-us-relations-warm-up-66865.html Pharmaxis shares spike ahead of promising year https://www.proactiveinvestors.com.au/companies/news/156134/pharmaxis-shares-spike-ahead-of-promising-year-66540.html Tue, 12 Jan 2016 23:30:00 +1100 https://www.proactiveinvestors.com.au/companies/news/156134/pharmaxis-shares-spike-ahead-of-promising-year-66540.html Pharmaxis enhances outlook for cystic fibrosis treatment https://www.proactiveinvestors.com.au/companies/news/156133/pharmaxis-enhances-outlook-for-cystic-fibrosis-treatment-66199.html Tue, 15 Dec 2015 23:00:00 +1100 https://www.proactiveinvestors.com.au/companies/news/156133/pharmaxis-enhances-outlook-for-cystic-fibrosis-treatment-66199.html Pharmaxis pumps up cash as partnerships and products add value https://www.proactiveinvestors.com.au/companies/news/156132/pharmaxis-pumps-up-cash-as-partnerships-and-products-add-value-65250.html Fri, 23 Oct 2015 03:47:00 +1100 https://www.proactiveinvestors.com.au/companies/news/156132/pharmaxis-pumps-up-cash-as-partnerships-and-products-add-value-65250.html Pharmaxis' CEO Gary Phillips details clinical trials, Boehringer agreement https://www.proactiveinvestors.com.au/companies/news/156131/pharmaxis-ceo-gary-phillips-details-clinical-trials-boehringer-agreement-64877.html Mon, 05 Oct 2015 06:30:00 +1100 https://www.proactiveinvestors.com.au/companies/news/156131/pharmaxis-ceo-gary-phillips-details-clinical-trials-boehringer-agreement-64877.html Pharmaxis Limited drug trials success builds product confidence https://www.proactiveinvestors.com.au/companies/news/156130/pharmaxis-limited-drug-trials-success-builds-product-confidence-64662.html Mon, 21 Sep 2015 23:41:00 +1000 https://www.proactiveinvestors.com.au/companies/news/156130/pharmaxis-limited-drug-trials-success-builds-product-confidence-64662.html Pharmaxis shareholder BVF Partners adds to stake https://www.proactiveinvestors.com.au/companies/news/156129/pharmaxis-shareholder-bvf-partners-adds-to-stake-64454.html Thu, 10 Sep 2015 01:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/156129/pharmaxis-shareholder-bvf-partners-adds-to-stake-64454.html Pharmaxis, Synairgen collaborate on pulmonary fibrosis treatment https://www.proactiveinvestors.com.au/companies/news/156128/pharmaxis-synairgen-collaborate-on-pulmonary-fibrosis-treatment-63838.html Wed, 05 Aug 2015 05:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/156128/pharmaxis-synairgen-collaborate-on-pulmonary-fibrosis-treatment-63838.html Pharmaxis Limited substantial shareholder continues to buy shares https://www.proactiveinvestors.com.au/companies/news/156127/pharmaxis-limited-substantial-shareholder-continues-to-buy-shares-63231.html Thu, 02 Jul 2015 07:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/156127/pharmaxis-limited-substantial-shareholder-continues-to-buy-shares-63231.html Pharmaxis Limited substantial shareholder acquires further shares https://www.proactiveinvestors.com.au/companies/news/156126/pharmaxis-limited-substantial-shareholder-acquires-further-shares-62995.html Thu, 18 Jun 2015 04:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/156126/pharmaxis-limited-substantial-shareholder-acquires-further-shares-62995.html Pharmaxis closes landmark sale agreement with Boehringer Ingelheim https://www.proactiveinvestors.com.au/companies/news/156125/-pharmaxis-closes-landmark-sale-agreement-with-boehringer-ingelheim-62414.html Mon, 18 May 2015 07:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/156125/-pharmaxis-closes-landmark-sale-agreement-with-boehringer-ingelheim-62414.html Pharmaxis signs exclusive distribution and supply deal with Chiesi Farmaceutici https://www.proactiveinvestors.com.au/companies/news/156124/pharmaxis-signs-exclusive-distribution-and-supply-deal-with-chiesi-farmaceutici-62233.html Fri, 08 May 2015 00:30:00 +1000 https://www.proactiveinvestors.com.au/companies/news/156124/pharmaxis-signs-exclusive-distribution-and-supply-deal-with-chiesi-farmaceutici-62233.html These are the biggest ASX% Gainers intra-day https://www.proactiveinvestors.com.au/companies/news/156123/these-are-the-biggest-asx-gainers-intra-day-61220.html Thu, 12 Mar 2015 05:00:00 +1100 https://www.proactiveinvestors.com.au/companies/news/156123/these-are-the-biggest-asx-gainers-intra-day-61220.html Pharmaxis, Citation Resources among ASX % Gainers intra-day https://www.proactiveinvestors.com.au/companies/news/156122/pharmaxis-citation-resources-among-asx-gainers-intra-day-59780.html Wed, 24 Dec 2014 04:00:00 +1100 https://www.proactiveinvestors.com.au/companies/news/156122/pharmaxis-citation-resources-among-asx-gainers-intra-day-59780.html Pharmaxis Limited granted trading halt https://www.proactiveinvestors.com.au/companies/news/156121/pharmaxis-limited-granted-trading-halt-56058.html Fri, 04 Jul 2014 00:40:00 +1000 https://www.proactiveinvestors.com.au/companies/news/156121/pharmaxis-limited-granted-trading-halt-56058.html Pharmaxis’ share volume jumps https://www.proactiveinvestors.com.au/companies/news/156120/pharmaxis-share-volume-jumps-51877.html Tue, 14 Jan 2014 23:40:00 +1100 https://www.proactiveinvestors.com.au/companies/news/156120/pharmaxis-share-volume-jumps-51877.html Pharmaxis’ shares catch an uplift https://www.proactiveinvestors.com.au/companies/news/156119/pharmaxis-shares-catch-an-uplift-51053.html Wed, 11 Dec 2013 01:00:00 +1100 https://www.proactiveinvestors.com.au/companies/news/156119/pharmaxis-shares-catch-an-uplift-51053.html Pharmaxis’ Bronchitol cystic fibrosis treatment receives nod from Scotland health service https://www.proactiveinvestors.com.au/companies/news/156118/pharmaxis-bronchitol-cystic-fibrosis-treatment-receives-nod-from-scotland-health-service-51038.html Tue, 10 Dec 2013 08:00:00 +1100 https://www.proactiveinvestors.com.au/companies/news/156118/pharmaxis-bronchitol-cystic-fibrosis-treatment-receives-nod-from-scotland-health-service-51038.html Pharmaxis receives $776,646 in Australian Research Council grants for fibrotic research https://www.proactiveinvestors.com.au/companies/news/156117/pharmaxis-receives-776646-in-australian-research-council-grants-for-fibrotic-research-45232.html Fri, 05 Jul 2013 00:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/156117/pharmaxis-receives-776646-in-australian-research-council-grants-for-fibrotic-research-45232.html Pharmaxis Limited and Valeant Pharmaceuticals team up in Eastern European https://www.proactiveinvestors.com.au/companies/news/156116/pharmaxis-limited-and-valeant-pharmaceuticals-team-up-in-eastern-european-43571.html Wed, 22 May 2013 00:20:00 +1000 https://www.proactiveinvestors.com.au/companies/news/156116/pharmaxis-limited-and-valeant-pharmaceuticals-team-up-in-eastern-european-43571.html Pharmaxis Limited to reveal chronic respiratory trial results https://www.proactiveinvestors.com.au/companies/news/156115/pharmaxis-limited-to-reveal-chronic-respiratory-trial-results-42308.html Mon, 22 Apr 2013 00:40:00 +1000 https://www.proactiveinvestors.com.au/companies/news/156115/pharmaxis-limited-to-reveal-chronic-respiratory-trial-results-42308.html Pharmaxis appoints Brazilian distributor for Bronchitol® cystic fibrosis drug https://www.proactiveinvestors.com.au/companies/news/156114/pharmaxis-appoints-brazilian-distributor-for-bronchitol-cystic-fibrosis-drug-41836.html Wed, 10 Apr 2013 02:30:00 +1000 https://www.proactiveinvestors.com.au/companies/news/156114/pharmaxis-appoints-brazilian-distributor-for-bronchitol-cystic-fibrosis-drug-41836.html Pharmaxis Limited receives FDA letter for its cystic fibrosis drug https://www.proactiveinvestors.com.au/companies/news/156113/pharmaxis-limited-receives-fda-letter-for-its-cystic-fibrosis-drug-40953.html Tue, 19 Mar 2013 00:10:00 +1100 https://www.proactiveinvestors.com.au/companies/news/156113/pharmaxis-limited-receives-fda-letter-for-its-cystic-fibrosis-drug-40953.html Pharmaxis achieves Phase 3 clinical trial milestone for bronchiectasis https://www.proactiveinvestors.com.au/companies/news/156112/pharmaxis-achieves-phase-3-clinical-trial-milestone-for-bronchiectasis-40562.html Fri, 08 Mar 2013 00:20:00 +1100 https://www.proactiveinvestors.com.au/companies/news/156112/pharmaxis-achieves-phase-3-clinical-trial-milestone-for-bronchiectasis-40562.html Pharmaxis Bronchitol® drug review by FDA, due Thursday https://www.proactiveinvestors.com.au/companies/news/156111/pharmaxis-bronchitol-drug-review-by-fda-due-thursday-38814.html Mon, 28 Jan 2013 23:31:00 +1100 https://www.proactiveinvestors.com.au/companies/news/156111/pharmaxis-bronchitol-drug-review-by-fda-due-thursday-38814.html Pharmaxis’ cystic fibrosis drug approved in UK https://www.proactiveinvestors.com.au/companies/news/156110/pharmaxis-cystic-fibrosis-drug-approved-in-uk--35023.html Fri, 26 Oct 2012 04:30:00 +1100 https://www.proactiveinvestors.com.au/companies/news/156110/pharmaxis-cystic-fibrosis-drug-approved-in-uk--35023.html Pharmaxis receives European committee nod to move to marketing approval of cystic fibrosis drug https://www.proactiveinvestors.com.au/companies/news/156109/pharmaxis-receives-european-committee-nod-to-move-to-marketing-approval-of-cystic-fibrosis-drug--21073.html Sun, 23 Oct 2011 23:38:00 +1100 https://www.proactiveinvestors.com.au/companies/news/156109/pharmaxis-receives-european-committee-nod-to-move-to-marketing-approval-of-cystic-fibrosis-drug--21073.html Pharmaxis in pre-open pending re-examination of Bronchitol® https://www.proactiveinvestors.com.au/companies/news/156108/pharmaxis-in-pre-open-pending-re-examination-of-bronchitol-20849.html Mon, 17 Oct 2011 22:19:00 +1100 https://www.proactiveinvestors.com.au/companies/news/156108/pharmaxis-in-pre-open-pending-re-examination-of-bronchitol-20849.html Pharmaxis in pre-open pending European Bronchitol marketing application announcement https://www.proactiveinvestors.com.au/companies/news/156107/pharmaxis-in-pre-open-pending-european-bronchitol-marketing-application-announcement-16513.html Mon, 23 May 2011 07:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/156107/pharmaxis-in-pre-open-pending-european-bronchitol-marketing-application-announcement-16513.html Pharmaxis Ltd buoyed by asthma study results https://www.proactiveinvestors.com.au/companies/news/156106/pharmaxis-ltd-buoyed-by-asthma-study-results-5594.html Thu, 11 Mar 2010 02:35:00 +1100 https://www.proactiveinvestors.com.au/companies/news/156106/pharmaxis-ltd-buoyed-by-asthma-study-results-5594.html Pharmaxis' Bronchitol inhaler has encouraging Phase 3 trial results for cystic fibrosis patients https://www.proactiveinvestors.com.au/companies/news/156105/pharmaxis-bronchitol-inhaler-has-encouraging-phase-3-trial-results-for-cystic-fibrosis-patients-1739.html Mon, 15 Jun 2009 21:21:00 +1000 https://www.proactiveinvestors.com.au/companies/news/156105/pharmaxis-bronchitol-inhaler-has-encouraging-phase-3-trial-results-for-cystic-fibrosis-patients-1739.html